Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar Belakang: Janus Kinase (JAK)-inhibitors telah digunakan untuk terapi beberapa penyakit inflamasi dan autoimun karena kemampuannya untuk mengendalikan respon imun dan cytokine release syndrome. Saat ini penggunaan baru dari Janus Kinase (JAK)-inhibitors diperuntukan untuk terapi coronavirus disease 2019 (Covid-19), namun bukti mengenai kegunaannya masih belum jelas. Penelitian ini dilakukan untuk menganalisa efikasi dari Janus Kinase (JAK)-inhibitors untuk mengurangi mortalitas pasien Covid-19.Tujuan: Mengetahui efek pemberian terapi Janus Kinase (JAK)-inhibitors terhadap mortalitas pasien Covid-19.Metode: Dengan menggunakan kata kunci spesifik, dilakukan pencarian artikel potensial secara komprehensif pada PubMed, Europe PMC, and ClinicalTrials.gov database dengan pembatasan waktu sampai 2 Juni 2021. Semua penelitian tentang Covid-19 dan JAK-inhibitors dimasukan. Analisa statistik dilakukan denganReview Manager 5.4 software.Hasil: 13 penelitian dengan 4339 pasien Covid-19 dimasukan dalam meta-analisis. Data kami menyimpulkan bahwa terapi JAK-inhibitors berhubungan dengan menurunnya mortalitas pasien Covid-19 (RR 0.52; 95%CI: 0.36-0.76, p=0.0006, I2 = 33%, random-effect modelling).Kesimpulan: Penelitian ini menyimpulkan terapi JAK-inhibitors berhubungan dengan menurunnya mortalitas pasien Covid-19. Namun dibutuhkan randomized clinical trials yang lebih banyak untuk mengkonfirmasi hasil penelitian ini.

---

Background: : Janus Kinase (JAK)-inhibitors have been used for treating several inflammatory and autoimmune disease because of its ability to restrains immune systems and cytokine release syndrome. Currently, JAK-inhibitors are repurposed for the treatment of coronavirus disease 2019 (Covid-19), however the evidence regarding their benefit are still unclear. This study sought to analyze the efficacy of JAK-inhibitors in improving the mortality outcomes of Covid-19 patients.

Objective: To determine the effect of JAK-inhibitors as therapy in Covid-19 patients related to mortality.

Methods: Using specific keywords, we comprehensively searched the potential articles on PubMed, Europe PMC, and ClinicalTrials.gov database until June 2nd, 2021. All published studies on Covid-19 and JAK-inhibitors were retrieved. Statistical analysis was conducted using Review Manager 5.4 software.

Results: A total of 13 studies with 4,339 Covid-19 patients were included in the meta-analysis. Our data suggested that JAK-inhibitors was associated with reduction of mortality from Covid-19 (RR 0.52; 95%CI: 0.36 – 0.76, p=0.0006, I2 = 33%, random-effect modelling).

Conclusion: Our study suggests that JAK-inhibitors may offer beneficial effects on Covid-19 mortality. However, more randomized clinical trials warrant to confirm the findings of our study."

"This book provides comprehensive insights into the latest basic and clinical developments in the field. The first part reviews recent findings and new technologies pertaining to basics of Jak-Stat function. The second part describes the evolution of Jak-Stat signaling and the role of the pathway in invertebrate organisms. The third part focuses on Jak-Stat signaling in hematopoietic cells under both physiological and pathophysiological conditions. Finally, chapters in the fourth section describe the relationship of Jak-Stat signaling to various states of disease, particularly infection, leukemias and solid cancers. The book is intended for all scientists in molecular biology, biochemistry and cell biology dealing with biomedical issues."